Liquid biopsies have recently captured the interest of a growing number of diagnostic players – It is currently one of the most exciting sectors of the in vitro diagnostics market. However, there are still some hurdles to be solved before they will become part of standard clinical testing.
Our mission is to change this by creatively tapping into the analytical potential of next-generation DNA sequencing.
Our technology combines molecular biology, next-gen-DNA sequencing (NGS) and artificial intelligence (AI)
In a clinical setting, only a fraction of genetic tests actually require sequencing the whole genome of an individual. Rather, typical use cases include targeted sequencing of just a few genomic areas, or detecting rare, untypical mutations against a healthy genetic background. This a typical a-needle-in-a-haystack situation, which causes challenges.
The next-generation sequencing (NGS) devices are highly sophisticated analytical platforms that permit such targeted, quantitative sequencing when applied in creative ways.
In our unique technology we combine molecular biology, next-gen-DNA sequencing (NGS) and artificial intelligence (AI) that enables substantial improvements in price, precision and turn-around time.